FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:827-828 August 19, 2004 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The story of the epidemic of severe acute respiratory syndrome (SARS) is a frightening one in many respects, but it provides heartening news about our ability to respond to an emergency. Less than 18 months after the first alerts of the disease were issued,¹ the causative virus has been isolated,² and Yang and colleagues have recently reported the efficacy of a prototype vaccine in a mouse model of infection.³ This advance was built on the back of a great deal of basic research^4,5 and thus underscores the wisdom of asking questions that are not necessarily geared toward known pathogens in . . . [Full Text of this Article]

Source Information

From the Carolina Vaccine Institute, University of North Carolina, Chapel Hill.

This article has been cited by other articles:

• Zhong, X., Guo, Z., Yang, H., Peng, L., Xie, Y., Wong, T.-Y., Lai, S.-T., Guo, Z. (2006). Amino terminus of the SARS coronavirus protein 3a elicits strong, potentially protective humoral responses in infected patients. J. Gen. Virol. 87: 369-373 [Abstract] [Full Text]  
• Yi, C. E., Ba, L., Zhang, L., Ho, D. D., Chen, Z. (2005). Single Amino Acid Substitutions in the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Determine Viral Entry and Immunogenicity of a Major Neutralizing Domain. J. Virol. 79: 11638-11646 [Abstract] [Full Text]